Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24985962.
- Also identified by DOI 10.1016/j.eururo.2014.05.038.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Neoplasms, Hormone-Dependent
- Prostatic Neoplasms